Resource Hub
VIRTUAL TOUR
CONTACT US
Our Company
About Us
Our Journey
Leadership
Scientific and BD Team
Aragen Advantage
Global Locations
Media & Events
Recognitions
Services
Small Molecules
Discovery
Integrated Drug Discovery
Chemistry
Biology
BioSafety
Development & Manufacturing
Drug Substance
Drug Product
Analytical Development
Performance Chemicals
Custom Chemical Synthesis
Commercial Manufacturing
Large Molecules (Biologics)
Discovery
Integrated Discovery
Biology
Molecular Biology
Antibody Discovery
Protein Sciences
Cell Line Development
Development & Manufacturing
Process Research & Development
Bioproduction
Developability & Analytics
GMP Manufacturing
Investors
Annual Reports and Annual Returns
Corporate Governance
Our Responsibility
Digital & AI (DnA)
EHS & Sustainability
Strategic Supply Chain Management
Quality
IP Protection & Data Security
Employee Welfare
Corporate Social Responsibility
Corporate Governance
Careers
Working at Aragen
Career Opportunities
Meet Our People
Caution Notice
Virtual Tour
Resources
Close Search
Search
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
GET IN TOUCH
Back to Resources
On-demand Webinars
Filter by Science
All
All
Analytical
Biologics
Biology
Chemistry
Development
Drug Substance
Formulations BU
Manufacturing
PCET
SAS/Toxicology
Reproductive and developmental toxicity studies for small molecules, large molecules, biologics, and vaccines
Advanced In Vivo Efficacy Models for Preclinical Success
Accelerating Small Molecule Drug Product Development
Advancing Biologics Development at Aragen
Advances in HPAPI Development and Regulatory Strategy
Enhancing mAb Platform Process using Membrane Affinity Chromatography for FIH Molecules
PROTACs: Breaking Boundaries in Drug Discovery
Process Development of New Chemical Entities — Overcoming Challenges of Safety and Quality for a Seamless Technology Transfer
Enabling Clinical Development of Poorly Soluble Molecules Through Formulation Solutions
Accelerating Biologics Development to Medicines: Key Drivers of Success
Development of Covalent Drugs with New Emerging Technologies
Brain Metastases – Challenges of Developing Clinically Relevant Preclinical Models
Driving Better Titers and Shorter Timelines with a Robust and Scalable CHO DG44 Platform
The Role of Protein Analytics in the Advancement of Biotherapeutic Drug Discovery & Development
Upstream Process Development for Better Yield and Product Quality
Amorphous Solid Dispersion — An Ideal Formulation Approach to Improve Developability of Poorly Soluble Molecules
Learn more about our end-to-end capabilities
+
+
